NasdaqGS - Nasdaq Real Time Price • USD
Bio-Techne Corporation (TECH)
As of 1:33 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 12 |
| Avg. Estimate | 0.45 | 0.5 | 1.77 | 2.04 |
| Low Estimate | 0.42 | 0.45 | 1.68 | 1.9 |
| High Estimate | 0.5 | 0.52 | 1.9 | 2.22 |
| Year Ago EPS | 0.53 | 0.55 | 1.99 | 1.77 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 12 | 11 |
| Avg. Estimate | 292.31M | 304.68M | 1.15B | 1.25B |
| Low Estimate | 288.5M | 300M | 1.14B | 1.23B |
| High Estimate | 295.2M | 310.4M | 1.16B | 1.25B |
| Year Ago Sales | -- | 301.32M | 1.14B | 1.15B |
| Sales Growth (year/est) | -- | 1.10% | 0.90% | 8.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.53 | 0.55 | 0.43 | 0.41 |
| EPS Actual | 0.53 | 0.55 | 0.41 | 0.4 |
| Difference | 0 | 0 | -0.02 | -0.01 |
| Surprise % | 0.00% | 0.00% | -4.70% | -2.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.45 | 0.5 | 1.77 | 2.04 |
| 7 Days Ago | 0.45 | 0.5 | 1.77 | 2.05 |
| 30 Days Ago | 0.45 | 0.5 | 1.75 | 2.02 |
| 60 Days Ago | 0.45 | 0.5 | 1.75 | 2.02 |
| 90 Days Ago | 0.49 | 0.53 | 1.85 | 2.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | TECH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -15.10% | -- | -- | 1.30% |
| Next Qtr. | -9.10% | -- | -- | 10.60% |
| Current Year | -11.10% | -- | -- | 5.10% |
| Next Year | 15.30% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 5.56% | -- | -- | 11.21% |
| Past 5 Years (per annum) | 14.55% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Deutsche Bank: Buy to Buy | 4/18/2024 |
| Maintains | Stephens & Co.: Overweight to Overweight | 2/2/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 2/2/2024 |
| Downgrade | Stifel: Buy to Hold | 2/2/2024 |
| Initiated | UBS: Buy | 12/7/2023 |
| Maintains | Stifel: Buy to Buy | 11/2/2023 |
Related Tickers
UTHR United Therapeutics Corporation
236.12
+0.88%
LEGN Legend Biotech Corporation
46.10
-2.04%
PCVX Vaxcyte, Inc.
61.86
+0.42%
ASND Ascendis Pharma A/S
146.03
+2.77%
INCY Incyte Corporation
52.11
+0.37%
GMAB Genmab A/S
28.79
-0.62%
BMRN BioMarin Pharmaceutical Inc.
91.97
+2.77%
RVMD Revolution Medicines, Inc.
36.68
+0.69%
BPMC Blueprint Medicines Corporation
94.00
+3.74%
RPRX Royalty Pharma plc
27.88
+0.22%